Skip to main content

Table 4 Agreement between PSMA-PET/CT, γ-probe, germanium detector and histopathology in 267 subregions

From: Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer

Subregions with tissue samples (n = 267*)

Histopathology

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Positive

Negative

PSMA-PET/CT findings

Positive

83

5

79.8

96.9

94.3

88.3

Negative

21

158

γ-probe [CPSnorm]

Positive

64

6

62.1

96.3

91.4

80.2

Negative

39

158

Germanium detector [% IAlbm]§

Positive

74

5

71.2

96.9

93.7

84.0

Negative

30

158

  1. Exclusion of 8/275 subregions because a follow-up PSMA-PET/CT showed the persistence or progression of the PET-positive lesion(s) indicating that the LN(s) had not been removed at surgery
  2. PPV positive predictive value, NPV negative predictive value
  3. A PSMA-PET-positive lesion was defined as focal tracer accumulation greater than normal or physiological local background activity
  4. Cut-off used > 23 counts per second, decay corrected to 48 h and normalised to injected activity megabecquerel per kilogram lean body mass
  5. §Cut-off used > 0.276 tracer uptake (percent injected activity per kilogram lean body mass)